Head-to-head evidence
ustekinumab vs ustekinumab-aekn (Selarsdi)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-12 p40 · full Ulcerative Colitis pipeline
ustekinumab · Stelara
Marketed by Johnson & Johnson
NCT02407236 · Phase 3 · completed
Randomized, double-blind, placebo-controlled, adequately powered (n=961) Phase 3 trial with clinical remission (Mayo score-based, including endoscopic subscore) as the primary endpoint, and the primary comparisons were statistically significant in the favorable direction for both induction and maintenance phases (p<0.001 to p=0.002).
Next expected readout: April 2027 · NCT07303686 (registry estimate)
ustekinumab-aekn (Selarsdi)
Marketed by Alvotech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Crohn's Disease
Shared mechanism: IL-12 p40 · full Crohn's Disease pipeline
ustekinumab · Stelara
Marketed by Johnson & Johnson
NCT01369329 · Phase 3 · completed
Randomized, quadruple-blinded, placebo-controlled, adequately powered (n~741) Phase 3 trial with a clinical primary endpoint (CDAI-based response), and the primary comparison for both active doses reached statistical significance in the favorable direction versus placebo, satisfying the 'strong' definition.
Next expected readout: December 2026 · NCT06520397 (registry estimate)
ustekinumab-aekn (Selarsdi)
Marketed by Alvotech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ustekinumab's landscape · ustekinumab-aekn (Selarsdi)'s landscape